KEYNOTE-话题@MedSci

#KEYNOTE#

43篇内容 | 1958人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1703437, encodeId=76c21e0343779, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果, objectType=article, longId=180885, objectId=c2e718088544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2e718088544, replyNumber=0, likeNumber=104, createdTime=2020-09-02, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e718088544, moduleTitle=K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e718088544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703436, encodeId=a5b61e0343655, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=KEYNOTE-062引发的关于免疫治疗研究与临床实践的深度思考, objectType=article, longId=175258, objectId=1bc61e525822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bc61e525822, replyNumber=0, likeNumber=95, createdTime=2019-10-31, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bc61e525822, moduleTitle=KEYNOTE-062引发的关于免疫治疗研究与临床实践的深度思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bc61e525822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703435, encodeId=e1dd1e0343513, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, objectType=article, longId=174829, objectId=8b6f1e482903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b6f1e482903, replyNumber=0, likeNumber=79, createdTime=2019-11-02, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b6f1e482903, moduleTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b6f1e482903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703431, encodeId=18101e03431ad, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=2018 WCLC | 张力教授：Keynote－032结果公布，Keynote－033值得期待, objectType=article, longId=150100, objectId=a38a150100d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a150100d9, replyNumber=0, likeNumber=82, createdTime=2019-09-04, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a150100d9, moduleTitle=2018 WCLC | 张力教授：Keynote－032结果公布，Keynote－033值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38a150100d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703434, encodeId=d2071e0343471, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=【ASCO-GI 2019】KEYNOTE-181研究亮相2019 ASCO-GI，PD-1单抗首次为晚期食管癌患者带来生存获益！, objectType=article, longId=158426, objectId=8f861584265c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f861584265c, replyNumber=0, likeNumber=92, createdTime=2019-04-16, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f861584265c, moduleTitle=【ASCO-GI 2019】KEYNOTE-181研究亮相2019 ASCO-GI，PD-1单抗首次为晚期食管癌患者带来生存获益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f861584265c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703432, encodeId=8c9d1e034327c, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=【2018 ESMO】周彩存教授谈KEYNOTE-010三年随访数据及免疫治疗趋势, objectType=article, longId=152293, objectId=bb8d15229332, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb8d15229332, replyNumber=0, likeNumber=87, createdTime=2018-11-04, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb8d15229332, moduleTitle=【2018 ESMO】周彩存教授谈KEYNOTE-010三年随访数据及免疫治疗趋势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb8d15229332)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703429, encodeId=8efa1e0342938, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=ACC 2018：Simon Dack Keynote演讲者呼吁聚焦女性心血管疾病防治及领域进展, objectType=article, longId=132254, objectId=00db13225426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00db13225426, replyNumber=0, likeNumber=77, createdTime=2018-04-18, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00db13225426, moduleTitle=ACC 2018：Simon Dack Keynote演讲者呼吁聚焦女性心血管疾病防治及领域进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00db13225426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703433, encodeId=8e681e03433bd, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=【2018 ESMO】KEYNOTE-057研究：卡介苗治疗无效的高风险非肌层浸润性膀胱癌，帕博利珠单抗显疗效, objectType=article, longId=152388, objectId=65e815238817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e815238817, replyNumber=0, likeNumber=80, createdTime=2019-05-29, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e815238817, moduleTitle=【2018 ESMO】KEYNOTE-057研究：卡介苗治疗无效的高风险非肌层浸润性膀胱癌，帕博利珠单抗显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e815238817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703430, encodeId=9c611e03430ff, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=【2018 ASCO】免疫联合治疗NSCLC鳞癌再赢一局！KEYNOTE-407研究精彩抢先看, objectType=article, longId=138592, objectId=6ffc1385926a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ffc1385926a, replyNumber=0, likeNumber=77, createdTime=2018-07-11, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ffc1385926a, moduleTitle=【2018 ASCO】免疫联合治疗NSCLC鳞癌再赢一局！KEYNOTE-407研究精彩抢先看, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ffc1385926a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703427, encodeId=85721e0342794, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=J CLIN ONCOL: Pembrolizumab治疗晚期程序性死亡因子配体 1-阳性的子宫内膜癌的安全及抗肿瘤活性（KEYNOTE-028）, objectType=article, longId=102865, objectId=a98d102865b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a98d102865b0, replyNumber=0, likeNumber=94, createdTime=2018-01-08, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a98d102865b0, moduleTitle=J CLIN ONCOL: Pembrolizumab治疗晚期程序性死亡因子配体 1-阳性的子宫内膜癌的安全及抗肿瘤活性（KEYNOTE-028）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a98d102865b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703423, encodeId=cb8c1e0342333, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）, objectType=article, longId=92485, objectId=2590924851f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2590924851f, replyNumber=0, likeNumber=90, createdTime=2017-05-21, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2590924851f, moduleTitle=NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2590924851f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703425, encodeId=8ea71e034255b, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Lancet Oncol：Pembrolizumab获批一线联合化疗治疗晚期NSCLC（KEYNOTE-021）, objectType=article, longId=99235, objectId=8d3699235ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d3699235ae, replyNumber=0, likeNumber=85, createdTime=2017-11-22, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d3699235ae, moduleTitle=Lancet Oncol：Pembrolizumab获批一线联合化疗治疗晚期NSCLC（KEYNOTE-021）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d3699235ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703421, encodeId=8a5c1e03421c3, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), objectType=article, longId=87698, objectId=f06c8e69880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06c8e69880, replyNumber=0, likeNumber=81, createdTime=2017-09-14, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06c8e69880, moduleTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06c8e69880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703428, encodeId=0bec1e0342826, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), objectType=article, longId=106852, objectId=5c6a10685217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c6a10685217, replyNumber=0, likeNumber=75, createdTime=2018-03-10, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c6a10685217, moduleTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c6a10685217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703424, encodeId=dac81e034241b, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028), objectType=article, longId=94466, objectId=d9bf94466c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9bf94466c1, replyNumber=0, likeNumber=99, createdTime=2018-01-06, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9bf94466c1, moduleTitle=Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9bf94466c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703422, encodeId=c3731e0342257, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=首度针对血癌，KEYTRUDA获批治疗经典型霍奇金淋巴瘤（KEYNOTE-087）, objectType=article, longId=92204, objectId=295e922047c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=295e922047c, replyNumber=0, likeNumber=70, createdTime=2017-05-18, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=295e922047c, moduleTitle=首度针对血癌，KEYTRUDA获批治疗经典型霍奇金淋巴瘤（KEYNOTE-087）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=295e922047c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703426, encodeId=53c21e0342699, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001), objectType=article, longId=100336, objectId=ff47100336ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff47100336ed, replyNumber=0, likeNumber=74, createdTime=2018-04-17, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff47100336ed, moduleTitle=Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff47100336ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703420, encodeId=40741e034200f, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Lancet Oncol：Pembrolizumab配合化疗一线对晚期非鳞NSCLC有明显获益(KEYNOTE-021), objectType=article, longId=81880, objectId=e29e81880a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e29e81880a0, replyNumber=0, likeNumber=98, createdTime=2017-10-17, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e29e81880a0, moduleTitle=Lancet Oncol：Pembrolizumab配合化疗一线对晚期非鳞NSCLC有明显获益(KEYNOTE-021), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e29e81880a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703418, encodeId=020d1e034189b, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), objectType=article, longId=71408, objectId=4379e1408e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4379e1408e0, replyNumber=0, likeNumber=84, createdTime=2016-11-06, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4379e1408e0, moduleTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4379e1408e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703419, encodeId=e4b51e034198d, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）, objectType=article, longId=81794, objectId=916481e9401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=916481e9401, replyNumber=0, likeNumber=69, createdTime=2017-05-17, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=916481e9401, moduleTitle=JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=916481e9401)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

KEYNOTE

2020-05-29

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果

2020-09-02

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

KEYNOTE-062引发的关于免疫治疗研究与临床实践的深度思考

2019-10-31

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位

2019-11-02

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

2018 WCLC | 张力教授：Keynote－032结果公布，Keynote－033值得期待

2019-09-04

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

【ASCO-GI 2019】KEYNOTE-181研究亮相2019 ASCO-GI，PD-1单抗首次为晚期食管癌患者带来生存获益！

2019-04-16

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

【2018 ESMO】周彩存教授谈KEYNOTE-010三年随访数据及免疫治疗趋势

2018-11-04

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

ACC 2018：Simon Dack Keynote演讲者呼吁聚焦女性心血管疾病防治及领域进展

2018-04-18

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

【2018 ESMO】KEYNOTE-057研究：卡介苗治疗无效的高风险非肌层浸润性膀胱癌，帕博利珠单抗显疗效

2019-05-29

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

【2018 ASCO】免疫联合治疗NSCLC鳞癌再赢一局！KEYNOTE-407研究精彩抢先看

2018-07-11

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

J CLIN ONCOL: Pembrolizumab治疗晚期程序性死亡因子配体 1-阳性的子宫内膜癌的安全及抗肿瘤活性（KEYNOTE-028）

2018-01-08

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）

2017-05-21

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Lancet Oncol：Pembrolizumab获批一线联合化疗治疗晚期NSCLC（KEYNOTE-021）

2017-11-22

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012)

2017-09-14

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究)

2018-03-10

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028)

2018-01-06

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

首度针对血癌，KEYTRUDA获批治疗经典型霍奇金淋巴瘤（KEYNOTE-087）

2017-05-18

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001)

2018-04-17

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Lancet Oncol：Pembrolizumab配合化疗一线对晚期非鳞NSCLC有明显获益(KEYNOTE-021)

2017-10-17

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029)

2016-11-06

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

JCO：Pembrolizumab治疗黑色素瘤患者中PD-L1表达量与缓解时间呈正相关（KEYNOTE-001）

2017-05-17

科室
- - 订阅+
  - 更多科室
工具
服务